



CASE REPORT OF SEIZURE PROBABLY DUE TO OLANZAPINE

Dr. Pooja Dixit	Resident Doctor , Dept.of Psychiatry , [Ravindranathgore medical college udaipur] Rajasthan
Dr. Anilkumar khatik*	Resident Doctor ,Dept.of Psychiatry,[Ravindranathgore medical college udaipur] Rajasthan *Corresponding Author
Dr. Sumit Mittal	Resident Doctor ,Dept.of Psychiatry[Ravindranathgore medical college udaipur] Rajasthan

ABSTRACT

Second generation antipsychotics may be associated with electroencephalogram abnormalities. Occurrence of seizure with Olanzapine is very rare. Some time olanzapine can cause lower seizure threshold. We report the case of a 61 year old female with delusional disorder who developed new-onset generalized tonic-clonic seizure probably due to Olanzapine. Electroencephalogram showed epileptiform discharges. The seizure risk associated with Olanzapine was reviewed.

KEYWORDS : Olanzapine, seizure, side effects, drug-induced seizure.

INTRODUCTION:

Olanzapine is an atypical antipsychotic primarily used to treat schizophrenia and bipolar disorder. Common side effects include weight gain, movement disorders, dizziness, feeling tired, constipation, and dry mouth. Other side effects include low blood pressure with standing, allergic reactions, neuroleptic malignant syndrome, high blood sugar, seizures, gynecomastia, erectile dysfunction, and tardive dyskinesia.⁽¹⁾ Olanzapine can lower seizure threshold and induce epileptiform discharges.⁽²⁾

Olanzapine is one of the most commonly used antipsychotic agents, and chemically similar to clozapine. The dose-related enticement of seizure by Clozapine though is well known, and that of Olanzapine rare cause seizure. Among the trials conducted for FDA approval of drugs, the incidence of seizure was significantly higher in the Clozapine and Olanzapine groups.^[3] The premarketing trials have found incidence of seizures at 0.88%, which is comparable to other conventional antipsychotics.^[3] Despite its proconvulsant liability, the literature reporting seizures are sparse. Few case reports of fatal status epilepticus and myoclonic status have attributed Olanzapine as the causative agent.^[4,5] Hereby we are reporting a case of seizure in a patient taking Olanzapine .

CASE:

A 61 year old female brought by her son to psychiatric emergency with complaint of frothing from mouth, tonic-clonic movement, uprolling of eyes and loss of consciousness 3 hour back. Two year back she was diagnosed as delusional disorder (documented) and she was on Tab olanzapine 10mg and was maintained on this dose. But because of her husband died 1 month back she discontinued the medication. After that she gradually started irritability, suspiciousness for that 2 days back she again started tab olanzapine 20mg of the counter. She has no history of previous seizure attack, no history of any substance abuse. No any medical history. On examination she was conscious, partly oriented. No any other neurological finding present. Computed tomographic scan and metabolic investigations were normal. EEG showed generalized epileptiform discharge. Olanzapine was stopped and started sodium valproate for seizure. After 3 days she was discharge on tab sodium valproate 500mg bd and tab haloperidole 5mg bd. Next follow up we stopped the anticonvulsant with no recurrence of seizures and did not require anticonvulsant therapy.

DISCUSSION:

In this case study patient was develop seizures because she

suddenly started olanzapine over the counter in higher dose than previous dose. Seizure occurred only when patient on olanzapine and did not have seizure in the brief follow-up period of stopping it. No other alternative explanation could be found for sudden appearance of seizures in our case. The adverse event got repeated in our case but the trial for attribution by stopping and restarting the medicines could not be done owing to high fatal risk of the seizure. The objective evidence in the means of abnormal epileptiform discharge on EEG was noted. Thus concluding according to Naranjo algorithm with a score of 5, the seizure occurring in our case was probably due to Olanzapine.^[6] As none of these mono-neurotransmitters can explain the differential seizurogenic potential of psychotropic drugs, dual neurotransmitter/receptor imbalances have been hypothesized. Drugs with higher dopamine:acetylcholine imbalance, serotonin:acetylcholine imbalance, D1:D2 antagonism, alpha 1:alpha 2 antagonism, and alpha 1:D2 receptor affinities are observed with higher rate of convulsions. Drugs with more affinity on dopamine receptors in cortical compared to subcortical (hippocampal/nigrostriatal) areas have also been noted to increase seizure liability.^[7] Olanzapine is known to cause highest EEG changes, in 35-45% of cases, ^[8,9,10,11] among the non-Clozapine newer antipsychotics. ^[8,9,10,11] Atypicals have high propensity to cause EEG changes compared to typical antipsychotics.^[12] Generalized/focal symmetrical theta and delta waves are more commonly found abnormal activities followed by asymmetrical slow waves, sharp waves with phase reversals, and spike-and-slow wave patterns. The later severe epileptic changes were noted in up to 11-15% of cases on Olanzapine.^[6,10,11] EEG changes were noted at around 4-7 months of starting Olanzapine in most of the literature.^[3,4,10] As abnormal epileptiform discharge on EEG could be seen in most of the reported cases including our case, so regular EEG monitoring should be done in high risk patient.

CONCLUSION:

Electroencephalogram showed epileptiform discharges; results of computed tomographic scan and metabolic investigations were normal. His antipsychotic was changed to haloperidol, and the patient showed a significant improvement in psychotic symptoms with no recurrence of seizures and did not require anticonvulsant therapy. Olanzapine has a profile similar to that of clozapine and shares its seizure-inducing potential. Typical antipsychotics such as haloperidol might be a safer option for such patients. It would be beneficial to monitor EEG as a seizure preventive strategy in high risk patients on olanzapine like Old age,

organicity, epilepsy, hypertension, bipolar disorders, comorbid OCD (Behere, 2009), after the cost effectiveness being evaluated.

REFERENCES

1. "Olanzapine, Olanzapine Pamoate Monograph for Professionals". Drugs.com.AHFS. Retrieved 24 December 2018.
2. Behere RV1, Anjith D, Rao NP, Venkatasubramanian G, Gangadhar BNOlanzapine-induced clinical seizure: a case report. *ClinNeuropharmacol*. 2009 Sep-Oct;32(5):297-8. doi: 10.1097/WNF.0b013e3181a7fd00
3. Alper K, Schwartz KA, Kolts RL, Khan A. Seizure incidence in psychopharmacological clinical trials: An analysis of food and drug administration (FDA) summary basis of approval reports. *Biol Psychiatry*. 2007;62:345–54. [PubMed] [Google Scholar]
4. Wyderski RJ, Starrett WG, Abou-Saif A. Fatal status epilepticus associated with olanzapine therapy. *Ann Pharmacother*. 1999;33:787–9. [PubMed] [Google Scholar]
5. Camacho A, García-Navarro M, Martínez B, Villarejo A, Pomares E. Olanzapine-induced myoclonic status. *ClinNeuropharmacol*. 2005;28:145–7. [PubMed] [Google Scholar]
6. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. *ClinPharmacolTher*. 1981;30:239–45. [PubMed] [Google Scholar]
7. Torta R, Monaco F. Atypical antipsychotics and serotonergic antidepressants in patients with epilepsy: Pharmacodynamic considerations. *Epilepsia*. 2002;43(Suppl 2):8–13. [PubMed] [Google Scholar]
8. Tedrus GM, Fonseca LC, Bossoni AS. Epileptic seizures and olanzapine use: Two cases report. *J Epilepsy ClinNeurophysiolSci ELO Brasil*. 2007;13:29–31. [Google Scholar]
9. Centorrino F, Price BH, Tuttle M, Bahk WM, Hennen J, Albert MJ, et al. EEG abnormalities during treatment with typical and atypical antipsychotics. *Am J Psychiatry*. 2002;159:109–15. [PubMed] [Google Scholar]
10. Amann BL, Pogarell O, Mergl R, Juckel G, Grunze H, Muler C, et al. EEG abnormalities associated with antipsychotics: A comparison of quetiapine, olanzapine, haloperidol and healthy subjects. *Hum Psychopharmacol*. 2003;18:641–6. [PubMed] [Google Scholar]
11. Schuld A, Kühn M, Haack M, Kraus T, Hinze-Selch D, Lechner C, et al. A comparison of the effects of clozapine and olanzapine on the EEG in patients with schizophrenia. *Pharmacopsychiatry*. 2000;33:109–11. [PubMed] [Google Scholar]
12. Erbac O, Yilmaz M. The effects of typical and atypical antipsychotics on the electrical activity of the brain in a rat model. [Last accessed on 2016 May 18]; *J Clin Exp Invest*. 2013 4:279–84. Available from: <http://www.jceionline.org>. [Google Scholar]